Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sells $20,400.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $5.10, for a total value of $20,400.00. Following the completion of the transaction, the director now directly owns 68,334 shares of the company’s stock, valued at approximately $348,503.40. This trade represents a 5.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Abeona Therapeutics Trading Down 0.6 %

NASDAQ ABEO traded down $0.03 during trading hours on Tuesday, hitting $5.19. 406,367 shares of the company’s stock were exchanged, compared to its average volume of 314,281. The firm has a market cap of $225.61 million, a price-to-earnings ratio of -1.93 and a beta of 1.46. The stock has a 50-day simple moving average of $5.83 and a 200 day simple moving average of $5.72. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics Inc has a 1-year low of $3.05 and a 1-year high of $9.01.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in Abeona Therapeutics in the third quarter valued at approximately $84,000. Charles Schwab Investment Management Inc. bought a new position in shares of Abeona Therapeutics in the 3rd quarter worth $151,000. XTX Topco Ltd bought a new position in shares of Abeona Therapeutics in the 3rd quarter worth $160,000. JPMorgan Chase & Co. grew its position in Abeona Therapeutics by 74.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after purchasing an additional 28,606 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Abeona Therapeutics by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 2,434 shares in the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ABEO. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday, November 25th. Finally, StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 9th.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.